Copenhagen, 2015-05-13 11:44 CEST (GLOBE NEWSWIRE) -- Copenhagen, 13 May 2015 ─ Zealand Pharma (Nasdaq Copenhagen: ZEAL) (“Zealand”) announces that its Articles of Association have been amended to reflect the recent grant of warrants to the company’s Executive Management and employees, as announced in Company Announcement no. 20/2015 on 5 May 2015.
The grant of warrants is part of Zealand’s incentive scheme, which has the objective of attracting and retaining first-rate employees and helping to ensure a common short and long-term interest between the management and the shareholders of the company.
The amendment of Zealand’s Articles of Association entailed by the grant of warrants has today been registered with the Danish Business Authority. The new Articles of Association are attached to this announcement and are also available on the company’s website: www.zealandpharma.com .
●●●●●
For further information, please contact:
Britt Meelby Jensen, President and Chief Executive Officer Tel: +45 51 67 61 28, email: bmj@zealandpharma.com
Hanne Leth Hillman, Senior Vice President for Communications and Investor Relations Tel: +45 50 60 36 89, email: hlh@zealandpharma.com
About Zealand Pharma
Zealand Pharma A/S (“Zealand”) (Nasdaq Copenhagen: ZEAL) is a biotechnology company based in Copenhagen, Denmark. Zealand has leading expertise in the discovery, design and development of novel peptide medicines and possesses in-house competences also in clinical trial design and management with a therapeutic focus on metabolic diseases and acute care indications. The company is advancing a pipeline of novel wholly-owned medicines in development alongside a partnered product and development portfolio.
Zealand’s first invented medicine, lixisenatide, a once-daily prandial GLP-1 agonist for the treatment of Type 2 diabetes, is marketed globally (ex-US) as Lyxumia ® and in Phase III development as a single-injection combination with Lantus ® (LixiLan), both under a global license agreement with Sanofi. US regulatory submission of Lyxumia ® is planned for Q3 2015 with US and EU regulatory submissions of LixiLan expected in Q4 2015 and Q1 2016, respectively.
Zealand’s wholly-owned products include danegaptide (prevention of Ischemic Reperfusion Injury) in Phase II and the stable glucagon product, ZP4207 (treatment of severe hypoglycemia) in Phase I as well as several preclinical peptide therapeutics. Partnering represents an important component of strategy to leverage in-house expertise, share development risk in large clinical trials, provide funding and commercialize the company’s products. Zealand currently has global license agreements and partnerships with Sanofi, Helsinn Healthcare, Boehringer Ingelheim and Eli Lilly.
For further information: www.zealandpharma.com Follow us on Twitter @ZealandPharma
